Estados financieros detallados de OnKure Therapeutics, Inc. (OKUR): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $2.88, OKUR presenta beneficios negativos (P/E no significativo) y un ROE del -49.02%. La capitalización bursátil es de $117M.
Cuenta de Resultados (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $37000 | $50000 | 0 | 0 | 0 | $830000 |
| Beneficio Bruto | -$37000 | -$50000 | 0 | 0 | 0 | -$830000 |
| I+D | $15.9M | $28.1M | $25.9M | $32.1M | $43.8M | $48.3M |
| Generales y Administrativos | $3.6M | $11.6M | $3.9M | $4.8M | $10.6M | $14.7M |
| Gastos Operativos | $19.5M | $39.8M | $29.8M | $36.9M | $54.4M | $62.1M |
| Beneficio Operativo | -$19.6M | -$39.8M | -$29.8M | -$36.9M | -$54.4M | -$63.0M |
| EBITDA | -$19.4M | -$39.7M | -$29.1M | -$34.8M | -$51.7M | -$58.7M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | $300000 | 0 |
| Beneficio Antes de Impuestos | -$19.5M | -$39.8M | -$29.5M | -$35.3M | -$52.7M | -$59.5M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$19.5M | -$39.8M | -$29.5M | -$35.3M | -$52.7M | -$59.5M |
| BPA | $-7.74 | $-21.92 | $-2.21 | $-2.65 | $-3.95 | $-4.40 |
| BPA Diluido | $-7.74 | $-21.92 | $-2.21 | $-2.65 | $-3.95 | $-4.40 |
| Acciones en Circulación (Diluidas) | $2.5M | $1.8M | $13.3M | $13.3M | $13.3M | $13.5M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | -$203000 | 0 |
| Beneficio Operativo | -$15.5M | -$14.1M | -$15.6M | -$16.9M |
| EBITDA | -$14.5M | -$13.3M | -$15.0M | -$15.3M |
| Beneficio Neto | -$14.7M | -$13.5M | -$15.2M | -$15.3M |
| BPA | $-1.09 | $-0.99 | $-1.11 | $-0.31 |
| BPA Diluido | $-1.09 | $-0.99 | $-1.11 | $-0.31 |
Balance (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $53.6M | $124.7M | $11.5M | $29.9M | $110.8M | $59.0M |
| Inversiones a Corto | 0 | $23.0M | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $55.0M | $153.7M | $13.6M | $33.8M | $113.0M | $60.8M |
| Inmovilizado Material | $69000 | $212000 | $2.0M | $1.9M | $1.8M | $1.0M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $55.2M | $154.0M | $16.0M | $35.7M | $114.9M | $62.1M |
| Cuentas por Pagar | 0 | 0 | $2.5M | $3.4M | $3.0M | $1.4M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $4.6M | $6.2M | $5.5M | $7.3M | $10.5M | $5.9M |
| Deuda a Largo | $92.7M | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $97.3M | $6.8M | $70.4M | $137.6M | $11.1M | $5.9M |
| Reservas | -$45.0M | -$84.7M | -$57.1M | -$102.1M | -$154.7M | -$214.2M |
| Patrimonio Neto | -$42.1M | $147.2M | -$54.4M | -$101.8M | $103.8M | $56.2M |
| Deuda Total | $92.7M | 0 | $637000 | $674000 | $1.1M | $549000 |
| Deuda Neta | $39.1M | -$147.7M | -$10.9M | -$29.2M | -$109.7M | -$58.5M |
| Capital Circulante | $50.4M | $147.5M | $8.1M | $26.5M | $102.5M | $54.9M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $70.3M | $59.0M | $192.1M | $166.5M |
| Activos Totales | $72.8M | $62.1M | $198.7M | $179.4M |
| Pasivos Totales | $6.4M | $5.9M | $14.3M | $7.2M |
| Patrimonio Neto | $66.4M | $56.2M | $184.4M | $172.1M |
| Deuda Total | $687000 | $549000 | $409000 | $926000 |
Flujo de Caja (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$19.5M | -$39.8M | -$29.5M | -$35.3M | -$52.7M | -$59.5M |
| Amortizaciones | $37000 | $50000 | $387000 | $560000 | $662000 | $830000 |
| Compensación en Acciones | 0 | 0 | $48000 | $199000 | $4.5M | $11.6M |
| Cambio en Capital Circulante | $514000 | -$2.8M | $2.1M | $6000 | -$4.0M | -$4.8M |
| Flujo de Caja Operativo | -$18.5M | -$38.0M | -$27.0M | -$34.5M | -$51.1M | -$51.8M |
| Inversiones (CapEx) | -$24000 | -$198000 | -$1.1M | -$246000 | -$52000 | -$46000 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$18.6M | -$38.2M | -$28.1M | -$34.8M | -$51.2M | -$51.9M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$13.0M | -$11.5M | -$12.9M | -$10.4M |
| Inversiones (CapEx) | -$6000 | -$9000 | -$5000 | -$3000 |
| Flujo de Caja Libre | -$13.0M | -$11.5M | -$12.9M | -$10.4M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $3.0M | $3.0M | $2.8M | $3.0M |
Crecimiento y Márgenes (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Beneficio Neto (anual) | | -104.3% | +25.8% | -19.6% | -49.2% | -13.0% |
| Crecimiento BPA (anual) | | -183.2% | +89.9% | -19.9% | -49.1% | -11.4% |
| Cambio en Acciones (anual) | | -27.9% | +635.2% | +0.0% | +0.0% | +1.3% |
| Crecimiento FCF (anual) | | -105.7% | +26.4% | -23.9% | -47.1% | -1.4% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-7.38 | $-21.04 | $-2.11 | $-2.61 | $-3.84 | $-3.84 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $2.5M | $1.8M | $13.3M | $13.3M | $13.3M | $13.5M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -49.02% |
| Rentabilidad sobre capital invertido | -35.91% |
| Rentabilidad sobre activos | -32.73% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.01 |
| Ratio corriente | 26.75 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -3.15 |
Ratios Clave (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -19.38 | -3.90 | -10.54 | -6.26 | -2.18 | -0.66 |
| P/VC | -8.96 | 1.05 | -5.71 | -2.17 | 1.10 | 0.70 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |